Table 1.
Pretreatment | Mean EC50 (nM) | 95% confidence limits (nM) | Mean Emax (%) | 95% confidence limits (%) | n |
---|---|---|---|---|---|
Vehicle | 5.0 | 1.6 and 15.0 | 29.1 | 24.6 and 33.7 | 7 |
0.01 nM CBDA | 10.4 | 3.6 and 30.1 | 31.3 | 26.7 and 35.9 | 7 |
Vehicle | 11.4 | 5.0 and 25.9 | 29.2 | 25.1 and 33.3 | 7 |
0.1 nM CBDA | 43.9 | 21.9 and 88.1 | 45.1* | 39.8 and 50.3 | 7 |
Vehicle | 6.0 | 1.8 and 20.3 | 26.8 | 22.2 and 31.4 | 6 |
1.0 nM CBDA | 15.5 | 4.0 and 59.7 | 45.1* | 36.7 and 53.4 | 6 |
Vehicle | 12.6 | 5.3 and 30.0 | 29.1 | 25.2 and 33.0 | 7 |
10 nM CBDA | 43.7 | 21.1 and 90.2 | 46.8* | 40.9 and 52.8 | 7 |
Vehicle | 9.5 | 4.1 and 21.9 | 22.9 | 19.9 and 25.8 | 7 |
100 nM CBDA | 26.3 | 13.4 and 51.6 | 37.1* | 33.0 and 41.2 | 7 |
Vehicle | 7.8 | 3.1 and 19.8 | 31.7 | 26.7 and 36.7 | 6 |
1000 nM CBDA | 18.3 | 5.0 and 67.4 | 28.8 | 22.6 and 35.0 | 6 |
The 95% confidence limits of this mean value do not overlap with those of the mean value in the previous row, indicating it to be significantly greater than the mean value obtained from experiments with vehicle-treated membranes (P < 0.05). See also Figure 8.